Redmile Group, LLC Morpho Sys Ag Transaction History

Redmile Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$24.18 - $31.58 $17.7 Million - $23.2 Million	-733,699 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$23.24 - $26.76 $3.72 Million - $4.28 Million	-160,101 Reduced 17.91%	733,699 $17.7 Million
Q1 2019 May 15, 2019	SELL	$22.55 - $29.84 $40,590 - $53,712	-1,800 Reduced 0.2%	893,800 $20.3 Million
Q4 2018 Feb 14, 2019	SELL	$21.96 - $31.02 $94,428 - $133,386	-4,300 Reduced 0.48%	895,600 $22.6 Million
Q3 2018 Nov 14, 2018	SELL	$26.64 - $35.66 $9.85 Million - $13.2 Million	-369,900 Reduced 29.13%	899,900 $24 Million

Q2 2018 Aug 14, 2018	BUY	$25.15 - $30.6 $31.9 Million - $38.9 Million	1,269,800 New	1,269,800 $38.5 Million

11.3M

320K

1.1M

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Market Cap $2.54B
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.